SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Detalles Bibliográficos
Autores principales: Nuijten, M, Mickisch, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813753/
https://www.ncbi.nlm.nih.gov/pubmed/20051962
http://dx.doi.org/10.1038/sj.bjc.6605446
_version_ 1782176954027343872
author Nuijten, M
Mickisch, G
author_facet Nuijten, M
Mickisch, G
author_sort Nuijten, M
collection PubMed
description
format Text
id pubmed-2813753
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28137532011-01-05 SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival Nuijten, M Mickisch, G Br J Cancer Letter to the Editor Nature Publishing Group 2010-01-05 2010-01-05 /pmc/articles/PMC2813753/ /pubmed/20051962 http://dx.doi.org/10.1038/sj.bjc.6605446 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Nuijten, M
Mickisch, G
SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_full SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_fullStr SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_full_unstemmed SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_short SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
title_sort sun vs bevþifn in first-line mrcc therapy: no evidence for a statistically significant difference in progression-free survival
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813753/
https://www.ncbi.nlm.nih.gov/pubmed/20051962
http://dx.doi.org/10.1038/sj.bjc.6605446
work_keys_str_mv AT nuijtenm sunvsbevþifninfirstlinemrcctherapynoevidenceforastatisticallysignificantdifferenceinprogressionfreesurvival
AT mickischg sunvsbevþifninfirstlinemrcctherapynoevidenceforastatisticallysignificantdifferenceinprogressionfreesurvival

Ejemplares similares